Alan Nurden: Platelet Defects Explain Bleeding in EHDS Patients
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Mariia Kumskova et al, published in Blood:
“While the Ehlers-Danlos syndrome (EHDS) is basically defined as a connective tissue disorder linked to increased elasticity many patients also report easy bruising and hemorrhagic problems. In this online paper in Blood, Mariia Kumskova and her colleagues describe how the platelet defects in EHDS patients are caused by decreased αIIbβ3 activation due to abnormally low talin-1 phosphorylation and a decreased presence of GPVI and PAR1, receptors for collagen and thrombin respectively.
As these signaling abnormalities were reproduced in a mouse (Col5a1+/-) model, it is therefore probable that the platelet defects directly explain the bleeding confirming that EHDS patients also have an inherited platelet disorder.
Interestingly, just as in Glanzmann thrombasthenia (where alphaIIbbeta3 function is absent), previous studies have shown that while thrombotic risk is reduced for EHDS patients, rare cases still occur and the general cardiovascular burden is not mitigated. An original and impressive study.”
Title: Platelet defects in patients and mice with Ehlers-Danlos syndrome
Authors: Mariia Kumskova, Gagan D Flora, Manasa K. Nayak, Ivan Budnik, Aditi Jain, Rakesh B. Patel, Abhishek B Jha, Madankumar Ghatge, Neelam Chauhan, James V. Michael, Steven E. McKenzie, Anjali Sharathkumar, Janice M Staber, Steven R Lentz, Anil Chauhan
Read the Full Article on Blood.
Other articles featuring Alan Nurden on Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants